Longeveron raises $4.4M from warrant exercise, issues new warrants to fund Lomecel-B development

Longeveron Inc.

Gross proceeds of $4.4M from exercise of 1,697,891 existing warrants at $2.35/share.
Issued new unregistered warrants to purchase up to 3,395,782 shares at $2.50, 24-month term.
Proceeds for Lomecel-B development (HLHS, Alzheimer's) and general corporate purposes.
H.C. Wainwright acted as exclusive placement agent; fees include 7% cash fee and warrants.
Closing occurred June 18, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.